| Glofitamab studied in …STUDIED_INderived75 of 75show fewer |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | Aggressive Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · 75 trials list this drug (63 active) | — | — | Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06213311Phase 2 · recruiting A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma,Blastoid Variant Mantle Cell Lymphoma,Pleomorphic Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06534437Phase 2 · recruiting MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) · 75 trials list this drug (63 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04889716Phase 2 · active not recruiting CAR-T Followed by Bispecific Antibodies · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047080Phase 3 · active not recruiting An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06634589Phase 1/Phase 2 · recruiting A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies · 75 trials list this drug (63 active) | — | — | Malignant Neoplasm,B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06806033Phase 2 · recruiting Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003295Phase 2 · recruiting Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06624085Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200375recruiting An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393738Phase 1 · recruiting A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma,Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05533775Phase 1/Phase 2 · recruiting A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma · 75 trials list this drug (63 active) | — | — | Mature B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084936Phase 3 · recruiting A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07444710Phase 1 · not yet recruiting Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04077723Phase 1/Phase 2 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · 75 trials list this drug (63 active) | — | — | Burkitt Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04980222Phase 2 · active not recruiting A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169515Phase 1 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · 75 trials list this drug (63 active) | — | — | Primary Effusion Lymphoma,AIDS-Related Diffuse Large B-cell Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748364Phase 2 · not yet recruiting Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06570447Phase 2 · recruiting Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075696Phase 1/Phase 2 · active not recruiting A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06765317Phase 2 · recruiting A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717177Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04970901Phase 1 · active not recruiting A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) · 75 trials list this drug (63 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711483Phase 2 · not yet recruiting GLORY: Glofit-GemOx With Liso-Cel For Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07599423Phase 2 · not yet recruiting A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558604Phase 2 · recruiting Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07695896not yet recruiting Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04408638Phase 3 · active not recruiting A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03533283Phase 1/Phase 2 · active not recruiting An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06922604Phase 1 · suspended Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma · 75 trials list this drug (63 active) | — | — | Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07453095Phase 2 · recruiting Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04161248early Phase 1 · active not recruiting Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634289Phase 2 · not yet recruiting Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528352Phase 1 · recruiting External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06994169recruiting Glofitamab in Real Life · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07613788Phase 2 · not yet recruiting Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594899Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896163Phase 1/Phase 2 · terminated A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06050694Phase 2 · recruiting Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798156Phase 2 · active not recruiting Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192888Phase 1 · active not recruiting A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06481826recruiting Glofitamab in Chinese Patients With R/R DLBCL · 75 trials list this drug (63 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07480850Phase 2 · active not recruiting Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703686Phase 2 · completed Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy · 75 trials list this drug (63 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma,Indolent Adult Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460362Phase 2 · recruiting Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05800366Phase 2 · recruiting A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07387848Phase 2 · not yet recruiting Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357676Phase 1/Phase 2 · recruiting Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07326371Phase 2 · not yet recruiting Glofitamab Combined With CAR-T Therapy in R/R DLBCL · 75 trials list this drug (63 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043674Phase 2 · recruiting Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation · 75 trials list this drug (63 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06054776Phase 2 · recruiting Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05364424Phase 1 · completed A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07240194Phase 2 · recruiting The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06670105Phase 2 · withdrawn A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06996132Phase 2 · recruiting Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012980Phase 2 · not yet recruiting Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06552572Phase 2 · active not recruiting Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03467373Phase 1 · completed A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06071871Phase 2 · recruiting A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656221Phase 2 · not yet recruiting A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656234not yet recruiting The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05219513Phase 1 · terminated A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 75 trials list this drug (63 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06567366Phase 2 · not yet recruiting CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors · 75 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04914741Phase 1/Phase 2 · unknown A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) · 75 trials list this drug (63 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06497452unknown A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. · 75 trials list this drug (63 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04313608Phase 1 · completed A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657302Phase 1 · completed A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 75 trials list this drug (63 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833763Phase 2 · recruiting A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. · 75 trials list this drug (63 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |